

Third Quarter And Nine Months Financial Statements Announcement For The Period Ended 31 December 2015
(In accordance with International Financial Reporting Standards)

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a) An income statement (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

Consolidated Income Statement for the third quarter and nine months ended 31 December 2015

		The Group					
		3rd Quarter Ended			Nine Months Ended		
Note	31-Dec-15	31-Dec-14	Change	31-Dec-15	31-Dec-14	Change	
	US\$'000	US\$'000	%	US\$'000	US\$'000	%	
Revenue							
Product revenue	62,198	71,665	(13)	179,434	210,997	(15)	
Licensing and royalties revenue	1,449	5,801	(75)	11,250	21,465	(48)	
Total revenue	63,647	77,466	(18)	190,684	232,462	(18)	
Total cost of sales	(18,845)	(21,809)	(14)	(52,606)	(63,175)	(17)	
Gross profit	44,802	55,657	(20)	138,078	169,287	(18)	
Operating expenses							
Sales and marketing expenses	(21,670)	(22,801)	(5)	(61,834)	(75,684)	(18)	
General and administrative expenses	(8,041)	(9,632)	(17)	(23,956)	(29,736)	(19)	
Research and development expenses	(7,344)	(7,543)	(3)	(17,550)	(22,853)	(23)	
	(37,055)	(39,976)	(7)	(103,340)	(128,273)	(19)	
Profit from operations	7,747	15,681	(51)	34,738	41,014	(15)	
Other (expenses)/income, net	(1,655)	(535)	> 100	2,306	(933)	NM	
Financial income	1,877	2,153	(13)	5,748	5,699	1	
Financial expenses	(3,270)	(3,452)	(5)	(9,887)	(10,318)	(4)	
Profit before exceptional and non-operating items	4,699	13,847	(66)	32,905	35,462	(7)	
Amortisation of customer lists and patents	(4,441)	(4,720)	(6)	(13,597)	(13,919)	(2)	
Exceptional items							
Restructuring of operations	(219)	(2,476)	(91)	(4,179)	(1,966)	> 100	
Amalgamation exercise	(162)	-	NM	(162)	-	NM	
(Loss)/Profit before tax	(123)	6,651	NM	14,967	19,577	(24)	
Income tax	(1,014)	785	NM	(2,633)	2,653	NM	
Net (loss)/profit for the period	(1,137)	7,436	NM	12,334	22,230	(45)	
Attributable to:							
Equity holders of the Company	<u>(1,137)</u>	<u>7,436</u>		<u>12,334</u>	<u>22,230</u>		
(Loss)/Earnings per share (US cent)							
Before exceptional items							
Basic	(0.04)	0.58		0.99	1.43		
Diluted	(0.04)	0.58		0.99	1.41		
After exceptional items							
Basic	(0.07)	0.44		0.73	1.31		
Diluted	(0.06)	0.44		0.73	1.30		

NM - Not meaningful

Consolidated Statement of Comprehensive Income

	The Group					
	3rd Quarter Ended			Nine Months Ended		
	31-Dec-15	31-Dec-14	Change	31-Dec-15	31-Dec-14	Change
	US\$'000	US\$'000	%	US\$'000	US\$'000	%
Net (loss)/profit for the period	(1,137)	7,436	NM	12,334	22,230	(45)
Other comprehensive (loss)/income:						
Exchange differences on translation of financial statements of foreign subsidiaries	(14,831)	(1,104)	>100	(47,380)	(3,162)	>100
Total comprehensive (loss)/income	(15,968)	6,332		(35,046)	19,068	

Attributable to:

Equity holders of the Company	(15,968)	6,332	(35,046)	19,068
-------------------------------	----------	-------	----------	--------

Footnotes

¹ Weighted average ordinary shares issued ('000)	1,688,550	1,694,758	1,685,335	1,696,967
---	-----------	-----------	-----------	-----------

² Weighted average ordinary shares and equivalents outstanding ('000)	1,770,214	1,704,687	1,690,427	1,710,118
--	-----------	-----------	-----------	-----------

Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares.

Diluted earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares adjusted for the effects of dilutive options.

Notes to the Income Statements

A Product revenue

	The Group			
	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15	31-Dec-14	31-Dec-15	31-Dec-14
	US\$'000	US\$'000	US\$'000	US\$'000
Critical care products	2,534	3,970	10,278	12,002
Interventional cardiology products	53,395	62,707	155,937	185,704
Cardiac diagnostic	6,269	4,988	13,219	13,291
	<u>62,198</u>	<u>71,665</u>	<u>179,434</u>	<u>210,997</u>

B Sales and marketing expenses decreased 5% to US\$21.7 million for the quarter ended 31 December 2015 from US\$22.8 million for the quarter ended 31 December 2014 mainly due to reduced payroll related expenses and doubtful debt expenses.

C General and administrative expenses decreased 17% to US\$8.0 million from US\$9.6 million in the corresponding quarter of last year mainly due to lower share-based payment expenses and payroll related expenses.

D Research and development expenses decreased 3% to US\$7.3 million from US\$7.5 million in the quarter ended 31 December 2014 mainly due to lower clinical trial expenses.

E Profit from operations is determined after (charging)/crediting the following:

	The Group			
	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15	31-Dec-14	31-Dec-15	31-Dec-14
	US\$'000	US\$'000	US\$'000	US\$'000
Depreciation of property, plant and equipment	(1,390)	(1,747)	(4,230)	(5,459)
Amortisation of intangible assets (excluding customer lists and patents)	(473)	(265)	(1,426)	(771)
Realisation of deferred revenue	3,457	1,621	6,983	5,561
Write-back of doubtful trade debts, net	229	32	1,337	548
Write-back for doubtful non-trade debts, net	269	3	274	9
Inventories write-down, net	(358)	(649)	(1,222)	(4,726)
(Provision)/Reversal for warranty, net	(633)	10	(638)	(24)
Reversal/(Provision) for sales return	173	(164)	188	(656)
Impairment of property, plant and equipment	-	-	(58)	66
Property, plant and equipment written off	-	(2)	(7)	(75)
Inventories written off	(539)	(268)	(1,771)	(585)

F Other income/(expenses), net

	The Group			
	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15	31-Dec-14	31-Dec-15	31-Dec-14
US\$'000	US\$'000	US\$'000	US\$'000	
Gain/(loss) on disposal of property, plant and equipment, net	2	(2)	(3)	(1)
Foreign exchange (loss)/gain, net	(1,722)	(349)	2,352	(724)
Other miscellaneous income /(expenses), net	65	(184)	(43)	(208)
	<u>(1,655)</u>	<u>(535)</u>	<u>2,306</u>	<u>(933)</u>

For the quarter foreign exchange loss arose from the depreciation of EUR against USD during the period.

G Financial income

	The Group			
	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15	31-Dec-14	31-Dec-15	31-Dec-14
US\$'000	US\$'000	US\$'000	US\$'000	
Interest income				
- bank balances	242	276	680	985
- fixed deposits	1,615	1,856	5,010	4,653
- others	20	21	58	61
	<u>1,877</u>	<u>2,153</u>	<u>5,748</u>	<u>5,699</u>

H Financial expenses

	The Group			
	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15	31-Dec-14	31-Dec-15	31-Dec-14
US\$'000	US\$'000	US\$'000	US\$'000	
Interest expense				
- long term loan	(402)	(351)	(1,212)	(828)
- notes payable	(2,839)	(3,075)	(8,632)	(9,431)
- others	(29)	(26)	(43)	(59)
	<u>(3,270)</u>	<u>(3,452)</u>	<u>(9,887)</u>	<u>(10,318)</u>

1(b)(i) A balance sheet (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

Consolidated Balance Sheets as at 31 December 2015

	Note	The Group		The Company	
		31-Dec-15	31-Mar-15	31-Dec-15	31-Mar-15
		US\$'000	US\$'000	US\$'000	US\$'000
Non-Current Assets					
Property, plant and equipment		80,125	86,289	-	-
Investment in subsidiaries		-	-	584,716	584,716
Other investments	A	36,434	28,836	38,844	28,836
Intangible assets		120,295	134,875	13,498	12,199
Deposit pledged for bank loan		1,060	1,092	-	-
Goodwill		416,941	439,576	52,579	52,579
Deferred tax assets		247	258	-	-
Long term loan to third parties		1,500	1,500	-	-
Long term loans to subsidiaries		-	-	59,253	56,616
		<u>656,602</u>	<u>692,426</u>	<u>748,890</u>	<u>734,946</u>
Current Assets					
Inventories	C	44,353	44,474	-	-
Trade receivables	D	62,454	73,121	-	-
Other receivables		3,631	4,059	744	-
Deposits and prepayments	B	16,733	15,058	1,435	523
Due from subsidiaries (non-trade)		-	-	15,973	13,303
Due from subsidiaries (trade)		-	-	3,616	7,042
Short term loan to a third party		556	500	-	-
Deposits pledged for bank loans		20,804	47,793	-	-
Cash and cash equivalents		520,054	518,253	267,383	298,656
		<u>668,585</u>	<u>703,258</u>	<u>289,151</u>	<u>319,524</u>
Less:					
Current Liabilities					
Trade payables		7,242	6,605	-	-
Other payables		13,267	18,939	302	768
Accruals	E	22,947	26,702	1,371	2,291
Provisions		1,987	2,747	-	-
Due to subsidiaries (non-trade)		-	-	10,438	18,413
Provision for income tax		6,412	6,845	356	23
Deferred revenue, current portion	F	1,001	1,678	-	-
Finance lease liabilities, current portion		20	19	-	-
Borrowings	G	25,960	41,433	24,092	41,046
Contingent consideration		-	2,410	-	2,410
		<u>78,836</u>	<u>107,378</u>	<u>36,559</u>	<u>64,951</u>
Net Current Assets		589,749	595,880	252,592	254,573
Non-Current Liabilities					
Deferred tax liabilities		12,912	15,220	-	-
Deferred revenue, non-current portion	F	822	1,561	-	-
Finance lease liabilities, non-current portion		50	60	-	-
Borrowings	G	245,970	254,260	205,824	211,819
Other payable - non current		25	78	25	78
Pension funds		2,710	2,701	-	-
		<u>262,489</u>	<u>273,880</u>	<u>205,849</u>	<u>211,897</u>
		<u>983,862</u>	<u>1,014,426</u>	<u>795,633</u>	<u>777,622</u>
Capital and Reserves					
Share capital		118	117	118	117
Share premium		750,266	746,042	750,266	746,042
Treasury shares		(54,692)	(54,692)	(54,692)	(54,692)
Translation reserves		(1,753)	45,627	-	-
Other reserves		19,782	19,525	18,736	18,479
Accumulated profits		270,141	257,807	78,795	67,676
		<u>983,862</u>	<u>1,014,426</u>	<u>793,223</u>	<u>777,622</u>
Net assets values					
Net assets per share (US cent)		58.27	60.36	46.98	46.27
Footnote					
Number of shares in issue at end of period ('000)		<u>1,688,550</u>	<u>1,680,706</u>	<u>1,688,550</u>	<u>1,680,706</u>

Net assets per share is calculated by dividing the net assets by the number of shares in issue as at the balance sheet date.

Notes to the Balance Sheets

A	<u>Other investments</u>	<u>The Group</u>		<u>The Company</u>	
		<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000	<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000
	Available-for-sale				
	Unquoted convertible bonds, at cost	7,500	3,000	7,500	3,000
	Unquoted shares, at cost	17,934	14,836	20,344	14,836
		<u>25,434</u>	<u>17,836</u>	<u>27,844</u>	<u>17,836</u>
	Held for trading				
	Unquoted equity warrants, at cost	11,000	11,000	11,000	11,000
		<u>36,434</u>	<u>28,836</u>	<u>38,844</u>	<u>28,836</u>
B	<u>Deposits and prepayments</u>				
		<u>The Group</u>		<u>The Company</u>	
		<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000	<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000
	Deposits	1,351	881	-	162
	Prepayments	15,382	14,177	1,435	361
		<u>16,733</u>	<u>15,058</u>	<u>1,435</u>	<u>523</u>
C	<u>Inventories</u>			<u>The Group</u>	
				<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000
	Finished goods			23,324	22,636
	Work-in-progress			4,607	5,225
	Sub-assemblies			4,688	4,192
	Raw materials			11,218	11,507
	Goods-in-transit			516	914
	Total inventories at lower of cost and net realisable value			<u>44,353</u>	<u>44,474</u>
D	<u>Trade receivables</u>			<u>The Group</u>	
				<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000
	Trade receivables			66,899	79,075
	Less: allowance for doubtful trade debts			(4,445)	(5,954)
				<u>62,454</u>	<u>73,121</u>
	Movements in allowance for doubtful trade debts during the period were as follows:				
	At beginning of year			5,954	8,514
	Reversal for the year			(1,337)	(449)
	Written off against allowance			(195)	(555)
	Translation differences			23	(1,556)
	At end of year			<u>4,445</u>	<u>5,954</u>
E	<u>Accruals</u>			<u>The Group</u>	
		<u>The Group</u>		<u>The Company</u>	
		<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000	<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000
	Accrued operating expenses	11,323	15,034	1,371	2,291
	Accrued payroll expense	11,409	11,402	-	-
	Accrued purchases	214	266	-	-
		<u>22,947</u>	<u>26,702</u>	<u>1,371</u>	<u>2,291</u>
F	<u>Deferred revenue</u>				
	This relates to the deferred revenue from the cardiac diagnostic business which will be realised over the service contracts period.				
G	<u>Loans and borrowings</u>			<u>The Group</u>	
				<u>31-Dec-15</u> US\$'000	<u>31-Mar-15</u> US\$'000
	Cross-border loans			19,023	39,000
	Medium terms notes			211,204	216,708
	Mortgage loan			41,703	39,985
				<u>271,930</u>	<u>295,693</u>

1(b)(ii) Aggregate amount of group's borrowings and debt securities.

Amount repayable in one year or less, or on demand

As at 31-Dec-15	
Secured	Unsecured
US\$'000	US\$'000
25,980	-

As at 31-Dec-14	
Secured	Unsecured
US\$'000	US\$'000
41,452	-

Amount repayable after one year

As at 31-Dec-15	
Secured	Unsecured
US\$'000	US\$'000
246,020	-

As at 31-Dec-14	
Secured	Unsecured
US\$'000	US\$'000
254,320	-

Details of any collateral

- (i) The banking facilities of a subsidiary, amounting to approximately US\$1.2 million, granted by a bank are secured by corporate guarantees from the Company.
- (ii) The partially drawn mortgage loan facilities of a subsidiary, amounting to approximately US\$42.0 million, is secured by corporate guarantees from the Company and fixed deposit of S\$1.5 million.
- (iii) The finance lease obligations are secured on office equipment with net book values of approximately US\$60,000 (31 March 2015 : US\$71,000).
- (iv) The Company has been granted a US\$19 million credit facility for the purposes of facilitating cross-border cash management which has been secured by pledged deposits of a subsidiary.
- (v) Fixed rate notes of S\$300 million (approximate US\$212 million) issued by a subsidiary under the Group's medium term note programme are guaranteed by the Company.

1(c) A cash flow statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

Consolidated Statements of Cash Flow for the third quarter and nine months ended 31 December 2015

	The Group			
	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15	31-Dec-14	31-Dec-15	31-Dec-14
	US\$'000	US\$'000	US\$'000	US\$'000
Cash flows from operating activities				
(Loss)/Profit before tax	(123)	6,651	14,967	19,577
Adjustments:				
Amortisation of intangible assets	4,914	4,985	15,023	14,690
Realisation of deferred revenue	(3,457)	(1,621)	(6,983)	(5,561)
Bad debts written off	(162)	(366)	(196)	(366)
Impairment of property, plant and equipment	-	-	58	(66)
Impairment of intangible assets	-	-	50	-
Depreciation of property, plant and equipment	1,390	1,747	4,230	5,459
Property, plant and equipment written off	-	2	7	75
(Gain)/Loss on disposal of property, plant and equipment	(2)	2	5	1
Inventories written off	539	268	1,771	585
Write-back of doubtful trade debts, net	(229)	(32)	(1,337)	(548)
Write-back of doubtful non-trade debts	(269)	(3)	(274)	(9)
Provision/(Reversal) for warranty, net	633	(10)	638	24
(Reversal)/provision for sales return	(173)	164	(188)	656
Intangible assets written off	-	-	-	15
Share-based expenses	845	2,249	2,989	940
Inventories write down, net	358	649	1,222	4,726
Interest expenses	1,422	3,452	8,039	10,318
Interest income	(1,877)	(2,153)	(5,748)	(5,699)
Translation differences	581	23	(1,260)	(1,203)
Operating cash flows before working capital changes	4,390	16,007	33,013	43,614
Decrease/(Increase) in:				
Inventories	566	1,726	(2,816)	736
Trade and other receivables	2,620	2,490	12,732	2,699
(Decrease)/Increase in:				
Trade and other payables	(2,583)	(8,040)	(5,626)	(2,526)
Deferred revenue	2,538	1,502	5,544	5,385
Pension funds	-	-	-	77
Cash generated from operations	7,531	13,685	42,847	49,985
Income tax paid, net	(1,327)	(1,467)	(4,908)	(4,873)
Interest income received	1,876	2,153	5,748	5,699
Interest expenses paid	(431)	(377)	(6,475)	(6,686)
Net cash generated from operating activities	7,649	13,994	37,212	44,125
Cash flows from investing activities				
Purchase of other investments	(8,000)	-	(10,008)	-
Purchase of property, plant and equipment	(493)	(6,964)	(1,666)	(33,237)
Purchase of intangible assets	(2,090)	(1,099)	(6,859)	(4,582)
Proceeds from sale of property, plant and equipment	26	746	223	770
Net cash used in investing activities	(10,557)	(7,317)	(18,310)	(37,049)
Cash flows from financing activities				
Repayment of finance leases	(4)	(10)	(16)	42
Uplift restricted deposit on long-term bank borrowing	22,841	-	22,841	-
(Repayment)/proceeds for bank borrowings	(20,579)	6,975	(21,785)	24,879
Purchase of treasury shares	-	(6,658)	-	(6,658)
Proceeds from issuance of new shares	-	4	1,492	783
Net cash generated from financing activities	2,258	311	2,532	19,046
Net (decrease)/increase in cash and cash equivalents	(650)	6,988	21,434	26,122
Cash and cash equivalents at beginning of the period	523,686	525,872	518,253	511,788
Net effect of exchange rate changes on cash and cash equivalents	(2,982)	(9,837)	(19,633)	(14,887)
Cash and cash equivalents at end of the period (Note A)	520,054	523,023	520,054	523,023

Note to the consolidated statements of cash flows:

A. Cash and cash equivalents

Cash and cash equivalents consist of cash and bank balances, fixed deposits and money markets deposits. Cash and cash equivalents included in the consolidated statements of cash flows comprise the following balance sheet amounts:

	The Group			
	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15	31-Dec-14	31-Dec-15	31-Dec-14
	US\$'000	US\$'000	US\$'000	US\$'000
Cash and bank balances	133,342	281,630	133,342	281,630
Fixed deposits	356,195	227,847	356,195	227,847
Money markets deposits	30,517	13,546	30,517	13,546
	520,054	523,023	520,054	523,023

1(d) (i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Statement of changes in equity for the third quarter and nine months ended 31 December 2015

	Attributable to equity holders of the Company						Total Equity
	Share Capital	Share Premium	Treasury Shares	Translation Reserves	Other Reserves	Accumulated Profit	
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
The Group							
At 1 April 2015	117	746,042	(54,692)	45,627	19,525	257,807	1,014,426
Profit net of tax	-	-	-	-	-	12,334	12,334
Exchange differences on translation of financial statements of foreign subsidiaries	-	-	-	(47,380)	-	-	(47,380)
Total comprehensive income	-	-	-	(47,380)	-	12,334	(35,046)
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	1	1,492	-	-	-	-	1,493
Transfer of reserve pursuant to the exercise of share options	-	2,732	-	-	(2,732)	-	-
Share-based expenses	-	-	-	-	2,989	-	2,989
Total contributions by and distributions to owners	1	4,224	-	-	257	-	4,482
At 31 December 2015	118	750,266	(54,692)	(1,753)	19,782	270,141	983,862
At 1 April 2014	117	740,034	(48,792)	50,839	27,327	483,520	1,253,045
Profit net of tax	-	-	-	-	-	22,230	22,230
Exchange differences on translation of financial statements of foreign subsidiaries	-	-	-	(3,162)	-	-	(3,162)
Total comprehensive income	-	-	-	(3,162)	-	22,230	19,068
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	-	* 783	-	-	-	-	783
Transfer of reserve pursuant to the exercise of share options	-	300	-	-	(300)	-	-
Purchase of treasury shares	-	-	(6,658)	-	-	-	(6,658)
Share-based expenses	-	-	-	-	940	-	940
Total contributions by and distributions to owners	-	1,083	(6,658)	-	640	-	(4,935)
At 31 December 2014	117	741,117	(55,450)	47,677	27,967	505,750	1,267,178

Footnote

* Amounts are less than US\$1,000.

Statement of changes in equity for the third quarter and nine months ended 31 December 2015

	Attributable to equity holders of the Company						Total Equity
	Share Capital	Share Premium	Treasury Shares	Translation Reserves	Other Reserves	Accumulated Profit	
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
The Company							
At 1 April 2015	117	746,042	(54,692)	-	18,479	67,676	777,622
Profit net of tax representing total comprehensive income	-	-	-	-	-	11,119	11,119
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	1	1,492	-	-	-	-	1,493
Transfer of reserve pursuant to the exercise of share options	-	2,732	-	-	(2,732)	-	-
Share-based expenses	-	-	-	-	2,989	-	2,989
Total contributions by and distribution to owners	1	4,224	-	-	257	-	4,482
At 31 December 2015	118	750,266	(54,692)	-	18,736	78,795	793,223
At 1 April 2014	117	740,034	(48,792)	-	26,822	55,474	773,655
Profit net of tax representing total comprehensive income	-	-	-	-	-	19,805	19,805
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	- *	783	-	-	-	-	783
Transfer of reserve pursuant to the exercise of share options	-	300	-	-	(300)	-	-
Purchase of treasury shares	-	-	(6,658)	-	-	-	(6,658)
Share-based expenses	-	-	-	-	940	-	940
Total contributions by and distribution to owners	-	1,083	(6,658)	-	640	-	(4,935)
At 31 December 2014	117	741,117	(55,450)	-	27,462	75,279	788,525

Footnote

* Amounts are less than US\$1,000.

Note to the Statement of Changes in Equity:

Other reserves consist of the following:

	The Group		The Company	
	31-Dec-15 US\$'000	31-Dec-14 US\$'000	31-Dec-15 US\$'000	31-Dec-14 US\$'000
Employee share options reserve	13,557	22,283	13,557	22,283
Statutory reserve	1,046	505	-	-
Capital reserves	1,561	1,561	1,561	1,561
Equity component of convertible notes	3,618	3,618	3,618	3,618
	<u>19,782</u>	<u>27,967</u>	<u>18,736</u>	<u>27,462</u>

- 1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

A. Changes in share capital

For the quarter ended 31 December 2015, the Company issued no new ordinary shares. As at 31 December 2015, the issued ordinary shares (excluding treasury shares) is 1,688,549,965 shares of par value 1/150 US cent each.

B. Stock options and performance shares outstanding

As at 31 December 2015, options in respect of a total of 32,419,193 (31 March 2015: 31,665,213) ordinary shares of par value 1/150 US cent each and 4,390,000 (31 March 2015: 8,000,000) performance shares pursuant to Biosensors Performance Share Plan were outstanding.

- 1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.**

	As at 31-Dec-15 '000	As at 31-Mar-15 '000
Total number of issued shares	1,767,212	1,759,368
Less number of shares held as treasury shares	(78,662)	(78,662)
Number of shares in issue excluding treasury shares of the Issuer at end of period	<u>1,688,550</u>	<u>1,680,706</u>

- 1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

	Number of Treasury Shares '000
Balance as at 1 April 2015 and 31 December 2015	<u>78,662</u>

- 2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

The figures have not been audited nor reviewed by the auditors.

- 3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter).**

Not applicable.

- 4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.**

The Group has applied the same accounting policies and methods of computation in the financial statements for the current reporting period as in the audited financial statements for the financial year ended 31 March 2015 except for the adoption of new/revised IFRSs and IFRIC Interpretations that are effective for annual periods beginning on or after 1 April 2015.

- 5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.**

The Group adopted the new/revised IFRSs and IFRIC Interpretations that are effective for annual periods beginning on or after 1 April 2015. Changes to the Group's accounting policies have been made as required, in accordance with the transitional provisions in the respective IFRSs and IFRIC Interpretations.

The following are the new or amended IFRSs that are relevant to the Group:	Effective date
Amendments to IAS 19 – Defined Benefit Plans: Employee Contributions	1 July 2014
IFRS 2 – Share-based Payments	1 July 2014
IFRS 3 – Business Combinations	1 July 2014
IFRS 8 – Operating Segments	1 July 2014
IAS 16 – Property, Plant and Equipment and IAS 38 – Intangible Assets	1 July 2014
IAS 24 – Related Party Disclosures	1 July 2014
IFRS 13 – Fair Value Measurement	1 July 2014

The adoption of the above IFRSs and IFRIC interpretations do not have any significant impact on the financial statements of the Group.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

Earnings per ordinary share of the Group:-	3rd Quarter Ended		Nine Months Ended	
	31-Dec-15 US cent	31-Dec-14 US cent	31-Dec-15 US cent	31-Dec-14 US cent
(a) Based on the weighted average number of				
- Before exceptional items	(0.04)	0.58	0.99	1.43
- After exceptional items	(0.07)	0.44	0.73	1.31
(b) On a fully diluted basis				
- Before exceptional items	(0.04)	0.58	0.99	1.41
- After exceptional items	(0.06)	0.44	0.73	1.30
¹ Weighted average ordinary shares issued ('000)	<u>1,688,550</u>	<u>1,694,758</u>	<u>1,685,335</u>	<u>1,696,967</u>
² Weighted average ordinary shares and equivalents outstanding ('000)	<u>1,770,214</u>	<u>1,704,687</u>	<u>1,690,427</u>	<u>1,710,118</u>

Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares.

Diluted earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period, excluding ordinary shares purchased by the Company and held as treasury shares, adjusted for the effects of dilutive options.

7. Net asset value (for the issuer and group) per ordinary share based on issued share capital of the issuer at the end of the:-
(a) current financial period reported on; and
(b) immediately preceding financial year.

Net assets per ordinary share	As at	As at
	31-Dec-15 US cent	31-Mar-15 US cent
- Group	58.27	60.36
- Company	46.98	46.27
Number of shares in issue at end of period ('000)	<u>1,688,550</u>	<u>1,680,706</u>

Net assets per share is calculated by dividing the net assets by the number of ordinary shares in issue as at the balance sheet date.

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must include a discussion of the following:-
(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

Financial Review for the third quarter and nine months ended 31 December 2015

Overview:

In Q3 FY16, the Company continued to achieve operation efficiency from its cost reduction strategies, operating operating income excluding licensing and royalty revenue grew by 17% from the immediate preceding quarter. On the total revenue front, the Company's performance for the quarter was still dragged down by weak licensing revenue, negative FX and soft sales in China.

Revenue:

Total revenue, including licensing and royalty revenue, for the quarter decreased 18% to US\$63.6 million from US\$77.5 million in the previous year's corresponding quarter. Total product revenue for the quarter ended 31 December 2015 was US\$62.2 million, compared to US\$71.7 million recorded in the previous year's corresponding quarter. The cardiac diagnostic revenue increased to US\$6.3 million from US\$5.0 million in the previous year's corresponding quarter. Interventional Cardiology product revenue fell to US\$53.4 million from US\$62.7 million in the same quarter last year. Critical care product revenue fell to US\$2.5 million from the US\$4.0 million in the same quarter last year.

For the nine months ended 31 December 2015, total product revenue decreased 15% to US\$179.4 million from US\$211.0 million in the previous year's corresponding period, contributed mainly by reduced revenue in the interventional cardiology business unit as a result of market competition and pricing pressure. The decrease in licensing revenue and royalties for the nine months ended 31 December 2015 was due to a reduction in the licensee's DES sales in Japan, consequentially total revenue including licensing and royalty revenue decreased 18% to US\$190.7 million from US\$232.5 million in the previous year's corresponding period.

The table below shows the Group's revenue and the principal components of the revenue, as a percentage of total revenue, for the periods indicated:

<u>Revenue by business segments - 3rd Quarter</u>	<u>Q3 FY 2016</u> <u>US\$'000</u>	<u>%</u>	<u>Q3 FY 2015</u> <u>US\$'000</u>	<u>%</u>
Critical care	2,534	4%	3,970	5%
Interventional cardiology	53,395	84%	62,707	81%
Cardiac diagnostic	6,269	10%	4,988	6%
Total product revenue	62,198	98%	71,665	93%
Licensing and royalties revenue	1,449	2%	5,801	7%
Total revenue	63,647	100%	77,466	100%

<u>Revenue by business segments - Nine months ended</u>	<u>YTD FY 2016</u> <u>US\$'000</u>	<u>%</u>	<u>YTD FY 2015</u> <u>US\$'000</u>	<u>%</u>
Critical care	10,278	5%	12,002	5%
Interventional cardiology	155,937	82%	185,704	80%
Cardiac diagnostic	13,219	7%	13,291	6%
Total product revenue	179,434	94%	210,997	91%
Licensing and royalties revenue	11,250	6%	21,465	9%
Total revenue	190,684	100%	232,462	100%

Cost of sales and gross profit:

Overall gross margin for products for the quarter ended 31 December 2015 was comparable to 70% from the previous year's corresponding quarter.

The table below shows the Group's gross profit by business segments, as a percentage of segment revenue, for the periods indicated:

<u>Gross profit by business segments - 3rd Quarter</u>	<u>Q3 FY 2016</u> <u>US\$'000</u>	<u>Gross Margin</u> <u>%</u>	<u>Q3 FY 2015</u> <u>US\$'000</u>	<u>Gross Margin</u> <u>%</u>
Critical care	1,094	43%	1,669	42%
Interventional cardiology	38,560	72%	45,265	72%
Cardiac diagnostic	3,699	59%	2,922	59%
Total product gross profit	43,353	70%	49,856	70%
Licensing and royalties revenue	1,449	100%	5,801	100%
Total gross profit	44,802	70%	55,657	72%

<u>Gross profit by business segments - Nine months ended</u>	<u>YTD FY 2016</u> <u>US\$'000</u>	<u>Gross Margin</u> <u>%</u>	<u>YTD FY 2015</u> <u>US\$'000</u>	<u>Gross Margin</u> <u>%</u>
Critical care	4,500	44%	5,156	43%
Interventional cardiology	114,404	73%	134,847	73%
Cardiac diagnostic	7,924	60%	7,819	59%
Total product gross profit	126,828	71%	147,822	70%
Licensing and royalties revenue	11,250	100%	21,465	100%
Total gross profit	138,078	72%	169,287	73%

Operating expenses:

The Group's total operating expenses for the third quarter were US\$37.1 million compared to US\$40.0 million for the third quarter in the previous year. Total operating expenses as a percentage of product revenue for the quarter was 60%, compared to 56% in the same quarter of the previous year. For the nine months ended 31 December 2015, total operating expenses were US\$103.3 million compared to US\$128.3 million in the previous year.

- (i) Sales and marketing expenses
Sales and marketing expenses decreased 5% to US\$21.7 million for the quarter ended 31 December 2015 compared to US\$22.8 million for the quarter ended 31 December 2014. For the nine months ended 31 December 2015, the sales and marketing expenses were US\$61.8 million, comparing to US\$75.7 million in the corresponding period of last year. The decrease was from reduced payroll related expenses and doubtful debt expenses.
- (ii) General and administrative expenses
General and administrative expenses were US\$8.0 million for the quarter ended 31 December 2015 compared to US\$9.6 million in the previous year's corresponding quarter, a decrease of 17%. For the nine months ended 31 December 2015, compared to the corresponding period for last year, general and administrative expenses reduced to US\$24.0 million from US\$29.7 million. The decrease for the period was mainly due to lower share-based payment expenses and payroll related expenses.
- (iii) Research and development expenses
Research and development expenses decreased 3% to US\$7.3 million for the quarter ended 31 December 2015 compared to US\$7.5 million in the quarter ended 31 December 2014. For the nine months ended 31 December 2015, the research and development expenses were US\$17.5 million compared to US\$22.9 million for the same period in prior year. The decrease was mainly due to lower clinical trial expenses.
- (iv) Other operating income/(expenses)
Other operating expenses for the quarter was mainly due to exchange loss from the depreciation of EUR against USD during the period.

Net result after tax:

The net result for the quarter ended 31 December 2015 was a net loss after tax of US\$1.1 million as compared to a net profit after tax of US\$7.4 million for the same quarter in the previous year. The reduction was due to lower product and licensing revenue.

Use of proceeds from the issue of 4.875% fixed rate notes due 2017

The Company refers to its announcement on 23 January 2013 in relation to the issuance of an aggregate of S\$300 million (approximate US\$222 million) in principal amount of 4-year notes with interest at a rate of 4.875%, payable semi-annually in arrear.

As at 31 December 2015, out of the total net proceeds of S\$295.4 million (approximate US\$208.9 million) from the issuance of 4-year notes, the Company paid US\$86.7 million for the acquisition of the business of Spectrum Dynamics, technical know-how of DES and other unquoted investments.

The Company will continue to make periodic announcements on the utilisation of the proceeds from the notes issue as and when such proceeds are materially deployed.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not Applicable.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Although efforts have been put in to improve operating efficiency, the Company's operating results continue to be affected by the overall revenue reduction despite some savings from continuous operating efficiency enhancement, moving forward there are still a lot of market uncertainty including but not limited continuous ASP erosion, China overall market weakness, uncertainty of FX impact as well as our Japan sales transforming from licensing sales from Terumo to company's direct sales of BMX-J stents. Company is continue working toward taking necessary steps to mitigate these risks.

11. Dividend**(a) Current Financial Period Reported On**

Any dividend declared for the current financial period reported on? None

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year? None

(c) Date payable

Not applicable.

(d) Books closure date

Not applicable.

12. If no dividend has been declared/recommended, a statement to that effect.

No dividend has been declared or recommended during the period under review.

13. Interested person transactions

There were no new interested person transactions during the third quarter ended 31 December 2015 under Chapter 9 of the Listing Manual.

BY ORDER OF THE BOARD

Yoh-Chie Lu
Chairman
3 March 2016



Statement by Directors
Pursuant to SGX Listing Rule 705(4)

In the opinion of management, the accompanying unaudited consolidated interim financial statements have been prepared on a consistent basis with the March 31, 2015 audited consolidated financial statements. The unaudited consolidated financial statements are presented in accordance with International Financial Reporting Standards ("IFRS"). The preparation of consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods, and therefore the actual results may differ from those estimates. The consolidated interim financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto included in our FY 2014/15 annual report.

To the best of our knowledge, nothing has come to the attention of the Directors which may render the interim financial results to be false or misleading. Based on our knowledge, the financial statements and other financial information included in this report, present fairly in all material respects the financial conditions, results of operations and cash flows of the Group as of, and for, the periods presented in this announcement.

On Behalf of the Board

Yoh-Chie Lu
Chairman

Jose Calle Gordo
CEO

3 March 2016

BIOSENSORS INTERNATIONAL GROUP, LTD.

Registered Address : Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda
Mailing Address : 36 Jalan Tukang, Singapore 619266

www.biosensors.com